MorphoSys BLA For Cancer Drug Gets Priority Review From FDA
Zacks Investment Research | Mar 02, 2020 02:55AM ET
Germany-based MorphoSys AG (NASDAQ:MOR) announced today that the FDA has accepted its Biologics License Application (BLA) and granted Priority Review to lead pipeline candidate, tafasitamab.
Tafasitamab is the company’s experimental anti-CD19 antibody, which is being evaluated in combination with Revlimid for the treatment of relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL).
The BLA was submitted at the end of last year. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of Aug 30, 2020.
The FDA has informed the company that they are not currently planning to hold an advisory committee meeting to discuss the application.
The BLA was submitted based on the primary analysis data from the L-MIND trial of tafasitamab in combination with Bristol Myers’ (NYSE:BMY) Revlimid in patients with r/r DLBCL and the retrospective observational matched control cohort of Re-MIND, evaluating efficacy outcomes of r/r DLBCL patients who received lenalidomide monotherapy.
We note that Priority Review is granted to therapies that the FDA determines to have the potential to provide significant improvements in the treatment, diagnosis or prevention of serious conditions. This designation shortens the review period to six months compared to 10 months of standard review.
The above-mentioned combination was granted Breakthrough Therapy designation by the FDA in r/r DLBCL in 2017.
In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. (NASDAQ:XNCR) . Per the terms of the collaboration and licensing agreement, the FDA acceptance of the BLA of tafasitamab triggers an undisclosed milestone payment to be received by Xencor from MorphoSys.
A potential approval will boost growth prospects of this clinical-stage biopharmaceutical company, which primarily focuses on cancer treatments.
The company’s shares have gained 0.8% in the past year against the industry ’s decline of 11.5%.
Tafasitamab is being evaluated as a therapeutic option in B cell malignancies in several ongoing combination trials. The ongoing phase III study, B-MIND, assesses the combination of tafasitamab and bendamustine versus rituximab and bendamustine in r/r DLBCL. Additionally, tafasitamab is currently being evaluated in patients with relapsed/refractory CLL/SLL after discontinuation of a prior Bruton tyrosine kinase inhibitor therapy (e.g. Imbruvica) in combination with Zydelig or Venclexta.
Get The News You Want
Competition is stiff in this space from the likes of other approved drugs like Revlimid and other therapies.
Zacks Rank & A Stock to Consider
MorphoSys currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the healthcare sector is Regeneron Pharmaceuticals (NASDAQ:REGN) , currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here .
Regeneron’s 2020 earnings per share estimates have increased from $26.76 to $28.31 in the past 60 days.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.